BioVie Inc. (BIVI) Reports Significant Subgroup Improvements in Long COVID Trial

BioVie reported Phase 2 ADDRESS-LC trial results, showing significant improvements in pre-specified subgroups with higher baseline symptom burden, though the overall population did not meet statistical significance. The company plans to present new biomarker data on November 13.

Original reporting
Published Nov 2, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioVie Inc. (BIVI) Reports Significant Subgroup Improvements in Long COVID Trial — source image
Decision brief

The 30-second read

$BIVINeutralMed
01

Why it matters

The data provides a fresh catalyst that could influence short‑term trading, especially ahead of the upcoming biomarker presentation.

02

Market read

First‑time disclosure of subgroup efficacy in a Phase 2 trial; modest trading relevance pending further data.

03

What to watch

Potential regulatory scrutiny of subgroup analysis and the need for confirmatory Phase 3 data.

Relevance 8/10Novelty 8/10Timing: today

Background

BioVie released its Phase 2 ADDRESS‑LC trial results, highlighting subgroup improvements while the intent‑to‑treat cohort missed significance.

Company-level read

Ticker impact

$BIVINeutralMedium confidence
Context

Phase 2 ADDRESS-LC trial showed statistically significant improvements in pre‑specified subgroups, with overall population not significant; new biomarker data to be presented Nov 13.

Expected impact

modest upside as investors price in potential follow‑on data and possible trial redesign

Evidence & confidence

Positive subgroup data can lift sentiment, but the lack of overall significance limits the upside; market will wait for the Nov 13 biomarker presentation.

Market effects

May raise interest in biotech firms with similar Phase 2 designs, but overall sector impact limited.

US biotech market could see slight uptick in related stocks.

Limited; primarily relevant to investors tracking clinical‑trial pipelines.

Counterpoint

The lack of overall significance suggests the subgroup findings are statistical flukes; price could fall on broader market skepticism.

Key entities

  • BioVie Inc.

    US‑listed biotech developing therapies for long COVID.

Related articles

$BIVIHighAI 8/10

BioVie to present additional Parkinson’s drug data at international conference

BioVie Inc (BIVI, BIVIW) will present additional data on its experimental Parkinson's drug, bezisterim, at the AD/PD 2027 conference in Barcelona. The data, from the Phase 2 SUNRISE-PD trial, showed significant improvements in motor and non-motor symptoms for patients with higher inflammation. The company reported a 1.23-point improvement in treated patients versus a 1.21-point worsening in the placebo group, with a p-value of 0.0006.

$BIVIMedAI 8/10

BioVie identifies two Long COVID patient groups with distinct responses to bezisterim

BioVie Inc. (BIVI, BIVIW) reported that its Long COVID trial identified two patient groups with distinct responses to its drug bezisterim. High-inflammatory patients showed cognitive improvements, while others improved in fatigue and post-exertional malaise. The trial, involving 203 participants, did not reach statistical significance overall. BioVie plans to present more data at an upcoming conference.

$BIVIMed

BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary

BioVie reported a wider quarterly loss of $5.61M, or $0.68 per share, due to increased R&D expenses and lower interest income. The company is pre-revenue. Key programs, including Parkinson's disease and Long COVID, showed positive results. The Phase 3 liver program protocol is being finalized. According to the company, R&D expenses rose primarily due to the Long COVID Phase 2 program.